Pacific Biosciences of California, Inc. (PACB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1158838,
    "name": "Pacific Biosciences of California, Inc.",
    "stock_name": "Pacific Biosciences of California, Inc.",
    "full_name": "Pacific Biosciences of California, Inc.",
    "name_url": "stocks-analysis/pacific-biosciences-of-california-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.52",
    "chg": 0.2,
    "chgp": "8.62%",
    "dir": 1,
    "prev_price": "2.32",
    "mcapval": "375.46",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US69404D1081",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "16.5 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pacific-biosciences-of-california-inc-1158838-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Pacific Biosciences Stock Forms Golden Cross, Signals Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/pacific-biosciences-stock-forms-golden-cross-signals-bullish-breakout-ahead-3645241",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PacificBioscien_goldencross_3645241.png",
        "date": "2025-10-24 19:29:12",
        "description": "Pacific Biosciences of California, Inc. has recently achieved a Golden Cross, indicating potential upward momentum. The stock has outperformed the S&P 500 with a notable monthly increase, despite a challenging long-term performance. Recent bullish indicators suggest a shift in market sentiment, attracting investor attention to the company's recovery potential."
      },
      {
        "title": "Is Pacific Biosciences of California, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pacific-biosciences-of-california-inc-technically-bullish-or-bearish-3545889",
        "imagepath": "",
        "date": "2025-09-20 19:20:53",
        "description": "As of 25 August 2025, the technical trend for Pacific Biosciences of California, Inc. has changed from sideways to mildly bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe and bearish moving averages on the daily timeframe. Additionally, the Dow Theory indicates a mildly bearish stance on both weekly and monthly periods. \n\nIn terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -30.05% versus the S&P 500's 12.22%, and a one-year return of -33.68% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is Pacific Biosciences of California, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pacific-biosciences-of-california-inc-overvalued-or-undervalued-3542558",
        "imagepath": "",
        "date": "2025-09-20 17:55:54",
        "description": "As of 29 April 2021, the valuation grade for Pacific Biosciences of California, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 3.73, an EV to EBIT of -1.06, and an EV to EBITDA of -3.29. Comparatively, its peer, which has a valuation of risky, shows a P/E of -0.6779 and an EV to EBITDA of -4.2891, further highlighting the company's relative weakness.\n\nThe company's recent stock performance has been significantly underwhelming, with a year-to-date return of -30.05% compared to the S&P 500's 12.22%, and a staggering decline of -84.26% over the past five years against the S&P 500's 96.61% gain. This stark contrast reinforces the view that Pacific Biosciences is overvalued in its current state...."
      }
    ],
    "total": 8,
    "sid": "1158838",
    "stock_news_url": "https://www.marketsmojo.com/news/pacific-biosciences-of-california-inc-1158838"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Pacific Biosciences Stock Forms Golden Cross, Signals Bullish Breakout Ahead

2025-10-24 19:29:12

Pacific Biosciences of California, Inc. has recently achieved a Golden Cross, indicating potential upward momentum. The stock has outperformed the S&P 500 with a notable monthly increase, despite a challenging long-term performance. Recent bullish indicators suggest a shift in market sentiment, attracting investor attention to the company's recovery potential.

Is Pacific Biosciences of California, Inc. technically bullish or bearish?

2025-09-20 19:20:53

As of 25 August 2025, the technical trend for Pacific Biosciences of California, Inc. has changed from sideways to mildly bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe and bearish moving averages on the daily timeframe. Additionally, the Dow Theory indicates a mildly bearish stance on both weekly and monthly periods. In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -30.05% versus the S&P 500's 12.22%, and a one-year return of -33.68% compared to the S&P 500's 17.14%....

Is Pacific Biosciences of California, Inc. overvalued or undervalued?

2025-09-20 17:55:54

As of 29 April 2021, the valuation grade for Pacific Biosciences of California, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 3.73, an EV to EBIT of -1.06, and an EV to EBITDA of -3.29. Comparatively, its peer, which has a valuation of risky, shows a P/E of -0.6779 and an EV to EBITDA of -4.2891, further highlighting the company's relative weakness. The company's recent stock performance has been significantly underwhelming, with a year-to-date return of -30.05% compared to the S&P 500's 12.22%, and a staggering decline of -84.26% over the past five years against the S&P 500's 96.61% gain. This stark contrast reinforces the view that Pacific Biosciences is overvalued in its current state....

View All News